<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://jme.bmj.com">
<title>Journal of Medical Ethics recent issues</title>
<link>http://jme.bmj.com</link>
<description>Journal of Medical Ethics RSS feed -- recent issues</description>
<prism:publicationName>Journal of Medical Ethics</prism:publicationName>
<prism:issn>0306-6800</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/257?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/258?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/263?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/267?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/274?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/281?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/286?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/294?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/299?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/304?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/310?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/317?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/319?rss=1" />
  <rdf:li rdf:resource="http://jme.bmj.com/cgi/content/short/38/5/322?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.jme.bmj.com/homepage/JME_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.jme.bmj.com/homepage/JME_95x60.gif">
<title>Journal of Medical Ethics</title>
<url>http://hwmaint.jme.bmj.com/homepage/JME_95x60.gif</url>
<link>http://jme.bmj.com</link>
</image>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/257?rss=1">
<title><![CDATA[Highlights from this issue]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/257?rss=1</link>
<description><![CDATA[ <sec><st>Is NICE ageist?</st> <p>In the UK, new health technologies are assessed by the National Institute for Clinical Excellence (NICE). NICE determines the cost incurred for each additional quality-adjusted life-year (QALY) that the new technology provides over and above the currently standard treatment. Though there is considerable flexibility in the process, technologies which offer a cost-per-QALY of &pound;20 000-&pound;30 000 or less would normally be recommended for use. The thought is that, given a fixed total health budget, use of technologies with a higher cost-per-QALY will generally decrease aggregate health by displacing more cost-effective interventions.</p> <p>One criticism levelled at NICE maintains that its methodology is ageist. Since younger people typically have a longer life expectancy than older people, a life-saving treatment will tend to produce more QALYs in a younger person. So too will a quality-of-life-improving intervention, since it will improve quality of life over a longer period. The NICE approach might...]]></description>
<dc:creator><![CDATA[Douglas, T.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2012-100711</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2012-100711</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Vaccination programs]]></dc:subject>
<dc:title><![CDATA[Highlights from this issue]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>The concise argument</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>257</prism:startingPage>
<prism:endingPage>257</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/258?rss=1">
<title><![CDATA[National Institute for Health and Clinical Excellence appraisal and ageism]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/258?rss=1</link>
<description><![CDATA[
<p>The requirements of the UK Equality Act 2010 and some high profile criticism for using a potentially ageist methodology have prompted the National Institute for Health and Clinical Excellence (NICE) to assess the processes and methodology it uses to make appraisal decisions. This paper argues that NICE has established rigorous systems to protect against ageist decisions, has no track record of ageism and is well placed to meet the requirements of new UK equality legislation.</p>
]]></description>
<dc:creator><![CDATA[Stevens, A., Doyle, N., Littlejohns, P., Docherty, M.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100129</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100129</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Editor's choice]]></dc:subject>
<dc:title><![CDATA[National Institute for Health and Clinical Excellence appraisal and ageism]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Law, ethics and medicine</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>258</prism:startingPage>
<prism:endingPage>262</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/263?rss=1">
<title><![CDATA[Ageism and equality]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/263?rss=1</link>
<description><![CDATA[
<p>This paper rebuts suggestions made by Littlejohns et al that NICE is not ageist by analysing the concept of ageism. It recognises the constraints that finite resources impose on decision making bodies such as NICE and then makes a number of positive suggestions as to how NICE might more effectively and more justly intervene in the allocation of scarce resources for health.</p>
]]></description>
<dc:creator><![CDATA[Harris, J., Regmi, S.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100417</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100417</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:title><![CDATA[Ageism and equality]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Commentary</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>263</prism:startingPage>
<prism:endingPage>266</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/267?rss=1">
<title><![CDATA[Older peoples' attitudes towards euthanasia and an end-of-life pill in The Netherlands: 2001-2009]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/267?rss=1</link>
<description><![CDATA[
<sec><st>Introduction</st>
<p>With an ageing population, end-of-life care is increasing in importance. The present work investigated characteristics and time trends of older peoples' attitudes towards euthanasia and an end-of-life pill.</p>
</sec>
<sec><st>Methods</st>
<p>Three samples aged 64&nbsp;years or older from the Longitudinal Ageing Study Amsterdam (N=1284 (2001), N=1303 (2005) and N=1245 (2008)) were studied. Respondents were asked whether they could imagine requesting their physician to end their life (euthanasia), or imagine asking for a pill to end their life if they became tired of living in the absence of a severe disease (end-of-life pill). Using logistic multivariable techniques, changes of attitudes over time and their association with demographic and health characteristics were assessed.</p>
</sec>
<sec><st>Results</st>
<p>The proportion of respondents with a positive attitude somewhat increased over time, but significantly only among the 64&ndash;74 age group. For euthanasia, these percentages were 58% (2001), 64% (2005) and 70% (2008) (OR of most recent versus earliest period (95% CI): 1.30 (1.17 to 1.44)). For an end-of-life pill, these percentages were 31% (2001), 33% (2005) and 45% (2008) (OR (95% CI): 1.37 (1.23 to 1.52)). For the end-of-life pill, interaction between the most recent time period and age group was significant.</p>
</sec>
<sec><st>Conclusions</st>
<p>An increasing proportion of older people reported that they could imagine desiring euthanasia or an end-of-life pill. This may imply an increased interest in deciding about your own life and stresses the importance to take older peoples' wishes seriously.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Buiting, H. M., Deeg, D. J. H., Knol, D. L., Ziegelmann, J. P., Pasman, H. R. W., Widdershoven, G. A. M., Onwuteaka-Philipsen, B. D.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100066</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100066</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[End of life decisions (geriatric medicine), End of life decisions (palliative care), Hospice, Assisted dying, End of life decisions (ethics)]]></dc:subject>
<dc:title><![CDATA[Older peoples' attitudes towards euthanasia and an end-of-life pill in The Netherlands: 2001-2009]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Law, ethics and medicine</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>267</prism:startingPage>
<prism:endingPage>273</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/274?rss=1">
<title><![CDATA[Are general practitioners prepared to end life on request in a country where euthanasia is legalised?]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/274?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>In 2002, Belgium set a legal framework for euthanasia, whereby granting and performing euthanasia is entrusted entirely to physicians, and&mdash;as advised by Belgian Medical Deontology&mdash;in the context of a trusted patient&ndash;physician relationship. Euthanasia is, however, rarely practiced, so the average physician will not attain routine in this matter.</p>
</sec>
<sec><st>Aim</st>
<p>To explore how general practitioners in Flanders (Belgium) deal with euthanasia. This was performed via qualitative analysis of semistructured interviews with 52 general practitioners (GPs).</p>
</sec>
<sec><st>Results</st>
<p>Although GPs can understand a patient's request for euthanasia, their own willingness to perform it is limited, based on their assumption that legal euthanasia equates to an injection that ends life abruptly. Their willingness to perform euthanasia is affected by the demanding nature of a patient's request, by their views on what circumstances render euthanasia legitimate and by their own ability to inject a lethal dose. Several GPs prefer increasing opioid dosages and palliative sedation to a lethal injection, which they consider to fall outside the scope of euthanasia legislation.</p>
</sec>
<sec><st>Conclusions</st>
<p>Four attitudes can be identified: (1) willing to perform euthanasia; (2) only willing to perform as a last resort; (3) feeling incapable of performing; (4) refusing on principle. The situation where GPs have to consider the request and&mdash;if they grant it&mdash;to perform the act may result in arbitrary access to euthanasia for the patient. The possibility of installing transparent referral and support strategies for the GPs should be further examined. Further discussion is needed in the medical profession about the exact content of the euthanasia law.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Sercu, M., Pype, P., Christiaens, T., Grypdonck, M., Derese, A., Deveugele, M.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100048</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100048</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[General practice / family medicine, End of life decisions (geriatric medicine), End of life decisions (palliative care), Assisted dying, End of life decisions (ethics)]]></dc:subject>
<dc:title><![CDATA[Are general practitioners prepared to end life on request in a country where euthanasia is legalised?]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Law, ethics and medicine</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>274</prism:startingPage>
<prism:endingPage>280</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/281?rss=1">
<title><![CDATA[The gap between voluntary admission and detention in mental health units]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/281?rss=1</link>
<description><![CDATA[
<p>This paper presents the case of a young man with a diagnosis of schizophrenia, who agreed to inpatient treatment primarily to avoid being formally detained. I draw on Peter Breggin's early critique of coercion of informal patients to supply an updated discussion of the ethical issues raised. Central questions are whether the admission was coercive, and if so, whether unethical. Whether or not involuntary admission would be justified, moral discomfort surrounds its appearance as a threat. This arises in part from ambivalence about autonomy: although a &lsquo;choice&rsquo; is made, the threat of detention impinges on the patient's choice. Recent legal developments provide some experience of safeguarding those whose consent is not obtained. This highlights the lack of safeguards in this &lsquo;gap&rsquo; and suggests that we have the tools with which to begin to deal with the problem.</p>
]]></description>
<dc:creator><![CDATA[Bingham, R.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100187</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100187</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Psychology and medicine]]></dc:subject>
<dc:title><![CDATA[The gap between voluntary admission and detention in mental health units]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Law, ethics and medicine</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>281</prism:startingPage>
<prism:endingPage>285</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/286?rss=1">
<title><![CDATA[Ethics, human rights and HIV vaccine trials in low-income settings]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/286?rss=1</link>
<description><![CDATA[
<p>The massive growth in global health research in past decades has posed many challenges for its effective ethical oversight, not least of which is how best to provide effective protection of research participants. The extent of the HIV epidemic in sub-Saharan Africa in particular makes research into prevention technologies for HIV, including HIV vaccine research, a global priority. However, the need for vaccine research must be considered in conjunction with the individual's right to informed consent, which is based on the principle of respect for autonomy. One of the primary human rights violations likely to occur in the context of HIV vaccine research is that potential research participants may not fully understand what participation in research studies entails. People who elect to enrol in HIV vaccine trials are required to understand both the potential negative effects of participation (eg, discrimination) as well as complex scientific concepts such as randomisation and prophylaxis in order to be ethically enrolled. In this study, two vignettes are presented to illustrate two core issues in conducting phase III HIV vaccine trials in low-income countries&mdash;namely, (1) from the perspective of participants, the extent to which understanding is a prerequisite for consenting to participate in a trial, and (2) from the perspective of trial investigators, whether it is appropriate to persuade eligible people to enrol in a trial, even though their initial reaction is to decline to participate. These vignettes are used to analyse these issues through the prisms of research ethics and human rights in order to identify helpful synergies. It is argued that the human rights perspective provides a helpful lens on ethical issues.</p>
]]></description>
<dc:creator><![CDATA[London, L., Kagee, A., Moodley, K., Swartz, L.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100227</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100227</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Health policy, HIV/AIDS, Sexual health, Informed consent, Research and publication ethics, Health service research, Legal and forensic medicine, Human rights]]></dc:subject>
<dc:title><![CDATA[Ethics, human rights and HIV vaccine trials in low-income settings]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Research ethics</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>286</prism:startingPage>
<prism:endingPage>293</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/294?rss=1">
<title><![CDATA[Self-prescribed and other informal care provided by physicians: scope, correlations and implications]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/294?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>While it is generally acknowledged that self-prescribing among physicians poses some risk, research finds such behaviour to be common and in certain cases accepted by the medical community. Largely absent from the literature is knowledge about other activities doctors perform for their own medical care or for the informal treatment of family and friends. This study examined the variety, frequency and association of behaviours doctors report providing informally. Informal care included prescriptions, as well as any other type of personal medical treatment (eg, monitoring chronic or serious conditions).</p>
</sec>
<sec><st>Method</st>
<p>A survey was sent to 2500 randomly-selected physicians in Colorado, 600 individuals returned questionnaires with usable data. The authors hypothesised: (1) physicians would prescribe the same types of treatment at home as they prescribed professionally; and (2) physicians who informally prescribed addictive medications would be more likely to engage in other types of informal medical care.</p>
</sec>
<sec><st>Results</st>
<p>Physicians who wrote prescriptions for antibiotics, psychotropics and opioids at work were more likely to prescribe these medications at home. Those prescribing addictive drugs outside of the office treated more serious illnesses in emergency situations, more chronic conditions and more major medical/surgical conditions informally than did those not routinely prescribing addictive medications. Physicians reported a variety of informal care behaviour and high frequency of informal care to family and friends.</p>
</sec>
<sec><st>Discussion</st>
<p>The frequency and variety of informal care reported in this study strongly argues for profession-wide discussion about ethical and guideline considerations for such behaviour. These areas are discussed in the paper.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Gendel, M. H., Brooks, E., Early, S. R., Gundersen, D. C., Dubovsky, S. L., Dilts, S. L., Shore, J. H.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100167</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100167</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Cardiovascular medicine, Emergency medicine, Health education]]></dc:subject>
<dc:title><![CDATA[Self-prescribed and other informal care provided by physicians: scope, correlations and implications]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Clinical ethics</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>294</prism:startingPage>
<prism:endingPage>298</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/299?rss=1">
<title><![CDATA[Proceduralisation, choice and parental reflections on decisions to accept newborn bloodspot screening]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/299?rss=1</link>
<description><![CDATA[
<p>Newborn screening is the programme through which newborn babies are screened for a variety of conditions shortly after birth. Programmes such as this are individually oriented but resemble traditional public health programmes because they are targeted at large groups of the population and they are offered as preventive interventions to a population considered healthy. As such, an ethical tension exists between the goals of promoting the high uptake of supposedly &lsquo;effective&rsquo; population-oriented programmes and the goal of promoting genuinely informed decision-making. There is, however, a lack of understanding with regard to how parents experience the tension between promoting uptake and facilitating informed choice. This paper addresses this issue, and data are presented to show how aspects of the timing, presentation of information and procedural routinisation of newborn screening serves to impact on the decisions made by parents.</p>
]]></description>
<dc:creator><![CDATA[Nicholls, S. G.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100040</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100040</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Proceduralisation, choice and parental reflections on decisions to accept newborn bloodspot screening]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Clinical ethics</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>299</prism:startingPage>
<prism:endingPage>303</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/304?rss=1">
<title><![CDATA[How anonymous is 'anonymous'? Some suggestions towards a coherent universal coding system for genetic samples]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/304?rss=1</link>
<description><![CDATA[
<p>So-called &lsquo;anonymous&rsquo; tissue samples are widely used in research. Because they lack externally identifying information, they are viewed as useful in reconciling conflicts between the control, privacy and confidentiality interests of those from whom the samples originated and the public (or commercial) interest in carrying out research, as reflected in &lsquo;consent or anonymise&rsquo; policies. High level guidance documents suggest that withdrawal of consent and samples and the provision of feedback are impossible in the case of anonymous samples. In view of recent developments in science and consumer-driven genomics the authors argue that such statements are misleading and only muddle complex ethical questions about possible entitlements to control over samples. The authors therefore propose that terms such as &lsquo;anonymised&rsquo;, &lsquo;anonymous&rsquo; or &lsquo;non-identifiable&rsquo; be removed entirely from documents describing research samples, especially from those aimed at the public. This is necessary as a matter of conceptual clarity and because failure to do so may jeopardise public trust in the governance of large scale databases. As there is wide variation in the taxonomy for tissue samples and no uniform national or international standards, the authors propose that a numeral-based universal coding system be implemented that focuses on specifying incremental levels of identifiability, rather than use terms that imply that the reidentification of research samples and associated actions are categorically impossible.</p>
]]></description>
<dc:creator><![CDATA[Schmidt, H., Callier, S.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100181</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100181</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Confidentiality, Legal and forensic medicine]]></dc:subject>
<dc:title><![CDATA[How anonymous is 'anonymous'? Some suggestions towards a coherent universal coding system for genetic samples]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Genetics</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>304</prism:startingPage>
<prism:endingPage>309</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/310?rss=1">
<title><![CDATA[A survey of the perspectives of patients who are seriously ill regarding end-of-life decisions in some medical institutions of Korea, China and Japan]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/310?rss=1</link>
<description><![CDATA[
<sec><st>Purpose</st>
<p>The debate about the end-of-life care decision is becoming a serious ethical and legal concern in the Far-Eastern countries of Korea, China and Japan. However, the issues regarding end-of-life care will reflect the cultural background, current medical practices and socioeconomic conditions of the countries, which are different from Western countries and between each other. Understanding the genuine thoughts of patients who are critically ill is the first step in confronting the issues, and a comparative descriptive study of these perspectives was conducted by collaboration between researchers in all three countries.</p>
</sec>
<sec><st>Methods</st>
<p>Surveys using self-reporting paper questionnaire forms were conducted from December 2008 to April 2009 in Korea (six hospitals in two regions), China (five hospitals in four regions) and Japan (nine hospitals in one region). The subjects were patients who were critically ill who had been diagnosed as having cancer. A total of 235 participants (Korea, 91; China, 62; Japan, 52) were eventually recruited and statistically analysed.</p>
</sec>
<sec><st>Results</st>
<p>Most respondents had sometimes or often thought of their own death, mostly fear of &lsquo;separation from loved ones&rsquo;. They wanted to hear the news regarding their own condition directly and frankly from the physician. A quarter of them preferred making end-of-life care decisions by themselves, while many respondents favoured a &lsquo;joint decision&rsquo; with their family members. The most favoured proxy decision maker was the spouse, followed by the children. Most admitted the necessity of &lsquo;advance directives&rsquo; and agreed with artificial ventilation withdrawal in irreversible conditions. The most common reason was &lsquo;artificial prolongation of life is unnecessary&rsquo;. Most respondents agreed with the concept of active euthanasia; however, significant differences were sometimes observed in the responses according to variables such as patient's country of origin, age, gender and education level.</p>
</sec>
<sec><st>Conclusion</st>
<p>Patients in Far-Eastern countries gave various responses regarding end-of-life care decisions. Although familial input is still influential, most patients think of themselves as the major decision maker and accept the necessity of advance directives with Westernization of the society. Artificial ventilation withdrawal and even active euthanasia may be acceptable to them.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Ivo, K., Younsuck, K., Ho, Y. Y., Sang-Yeon, S., Seog, H. D., Hyunah, B., Kenji, H., Xiaomei, Z.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100153</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100153</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[End of life decisions (geriatric medicine), Child health, End of life decisions (palliative care), Hospice, Assisted dying, End of life decisions (ethics), Research and publication ethics]]></dc:subject>
<dc:title><![CDATA[A survey of the perspectives of patients who are seriously ill regarding end-of-life decisions in some medical institutions of Korea, China and Japan]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Global medical ethics</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>310</prism:startingPage>
<prism:endingPage>316</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/317?rss=1">
<title><![CDATA[A proposed non-consequentialist policy for the ethical distribution of scarce vaccination in the face of an influenza pandemic]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/317?rss=1</link>
<description><![CDATA[
<p>The current UK policy for the distribution of scarce vaccination in an influenza pandemic is ethically dubious. It is based on the planned outcome of the maximum health benefit in terms of the saving of lives and the reduction of illness. To that end, the population is classified in terms of particular priority groups. An alternative policy with a non-consequentialist rationale is proposed in the present work. The state should give the vaccination, in the first instance, to those who are at risk of catching the pandemic flu in the line of their duties of public employment. Thereafter, if there is not sufficient vaccine to give all citizens equally an effective dose, the state should give all citizens an equal chance of receiving an effective dose. This would be the just thing to do because the state has a duty to treat each and all of its citizens impartially and they have a corresponding right to such impartial treatment. Although this article specifically refers to the UK, it is considered that the suggested alternative policy would be applicable generally. The duty to act justly is not merely a local one.</p>
]]></description>
<dc:creator><![CDATA[McLachlan, H. V.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100031</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100031</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:title><![CDATA[A proposed non-consequentialist policy for the ethical distribution of scarce vaccination in the face of an influenza pandemic]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Brief report</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>317</prism:startingPage>
<prism:endingPage>318</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/319?rss=1">
<title><![CDATA[Intervening in clinical research to prevent the onset of psychoses: conflicts and obligations]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/319?rss=1</link>
<description><![CDATA[
<p>A prevailing issue in clinical research is the duty clinicians have to treat or prevent the progression of disease during a study that they are conducting. While all clinical researchers have a duty of care for the patients who participate in clinical research, intervening at the onset or progression of disease may skew results and have a negative impact on the scientific validity of a study. Extreme examples of failures to intervene can be found in the Tuskegee syphilis study and in an attempt to determine if cervical smears were an accurate predictor of cancer, which was uncovered by the Cartwright Inquiry. However, the issue arises in all research where delay in intervention can cause harm. A current study in Singapore is investigating the significance of an &lsquo;ultra-high risk&rsquo; state that may constitute the prodromal phase of psychosis. This project called &lsquo;The Longitudinal Youth at Risk Study&rsquo; is potentially contentious because it is recruiting young people who are identified as being &lsquo;at risk&rsquo; of developing psychosis. In this paper, the decision to offer treatment to all participants as well as a fast track for those who are assessed to have developed serious mental illness into treatment is discussed. It is argued that this approach is ethically justified because of the duty of care that is owed to research participants, and suggests that the principle of equipoise may be used to guide intervention decisions in other clinical research protocols.</p>
]]></description>
<dc:creator><![CDATA[Lysaght, T., Capps, B. J., Campbell, A. V., Subramaniam, M., Chong, S.-A.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2011-100008</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2011-100008</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[Sexual health, Psychology and medicine]]></dc:subject>
<dc:title><![CDATA[Intervening in clinical research to prevent the onset of psychoses: conflicts and obligations]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Brief report</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>319</prism:startingPage>
<prism:endingPage>321</prism:endingPage>
</item>
<item rdf:about="http://jme.bmj.com/cgi/content/short/38/5/322?rss=1">
<title><![CDATA[Ethics briefings]]></title>
<link>http://jme.bmj.com/cgi/content/short/38/5/322?rss=1</link>
<description><![CDATA[ <sec><st>Mental health right to life case</st> <p>In February 2012, the Supreme Court in England and Wales ruled that the NHS is under a duty to protect the right to life of suicidal psychiatric patients even if they are in hospital voluntarily.<cross-ref type="bib" refid="b1">1</cross-ref> As previously reported here,<cross-ref type="bib" refid="b2">2</cross-ref> the courts in England and Wales established in a 2008 case that hospitals and other health organisations owe a duty to patients detained under the Mental Health Act (MHA) to prevent them from taking their own lives. The 2012 case extended this duty so that it applies whether or not a patient has been formally detained.</p> <p>Having attempted suicide a number of times, Melanie Rabone was admitted to hospital as an informal patient in April 2005. She was assessed as a moderate to high suicide risk and a doctor noted that if she tried or demanded to leave she should...]]></description>
<dc:creator><![CDATA[Davies, M., Brannan, S., Chrispin, E., English, V., Mussell, R., Sheather, J. C.]]></dc:creator>
<dc:date>2012-04-18T17:20:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/medethics-2012-100635</dc:identifier>
<dc:identifier>hwp:master-id:medethics;medethics-2012-100635</dc:identifier>
<dc:publisher>Institute of Medical Ethics</dc:publisher>
<dc:subject><![CDATA[End of life decisions (geriatric medicine), End of life decisions (palliative care), Suicide (psychiatry), Assisted dying, End of life decisions (ethics), Ethics of abortion, Ethics of reproduction, Sex and sexuality, Suicide (public health)]]></dc:subject>
<dc:title><![CDATA[Ethics briefings]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Ethics briefings</prism:section>
<prism:volume>38</prism:volume>
<prism:number>5</prism:number>
<prism:startingPage>322</prism:startingPage>
<prism:endingPage>324</prism:endingPage>
</item>
</rdf:RDF>
